Corporate Governance & responsable Investing
Corporate governance is an integral component to the business of BB Biotech AG (the Company). The Board of Directors is committed to implement corporate governance policies which are aligned with the size and complexity of the Company’s activities.
Key governance principles
Clear Leadership
Our Board of Directors sets the governance framework and oversees its implementation in line with our size and complexity.
Regulatory Compliance
BB Biotech complies with the governance and disclosure standards required for companies listed on the Swiss and German exchanges.
We see ESG as part of how we invest and operate
Responsible Investing
ESG factors are considered in every potential investment, helping us assess risks and opportunities beyond financials.
Strategic Integration
Sustainability principles guide decision making at the Board, investment manager, and portfolio levels.
Active Engagement
We engage with portfolio companies on governance and impact issues and use proxy voting where appropriate.
Governance & oversight
Board committees (Audit, Risk, Governance, Compensation) with brief explanation of role
Separation of governance and management functions
Bellevue Asset Management’s regulatory oversight (FINMA) and license status
Depth of expertise: decades of combined experience across biotech, finance and corporate governance
Rigorous oversight: strategic governance supports disciplined investing
Scientific and financial integration: investment decisions informed by both disciplines
Stable leadership: continuity in board and investment management builds long-term confidence
Highlights
Included in the SIX Swiss ESG benchmark — showing our governance and sustainability commitments.
Reflecting progress on measurable ESG criteria and consistent improvement.
Governance in action
Audit & risk
Financial controls, risk framework, reporting quality.
Remuneration & nomination
Board composition, compensation strategy.
Sustainability & governance
ESG oversight and integration.
Directors' Dealings
Notification concerning transactions by persons performing managerial responsibilities pursuant to Article 19 MAR
Transaction of BB Biotech AG (ISIN CH0038389992, par value of CHF 0.20), Schwertstrasse 6, CH-8200 Schaffhausen done by the Board of Directors, the Management or close associates of these persons are reported here: https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html?companyId=SWISSF#/